{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:21:47Z","timestamp":1790727707835,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"A. Menarini Industrie Farmaceutiche Riunite S.R.L."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jgar.2020.09.027","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T12:57:47Z","timestamp":1602680267000},"page":"278-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014\u20132019)"],"prefix":"10.1016","volume":"23","author":[{"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.09.027_bib0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12879-015-0822-2","article-title":"Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study","volume":"15","author":"Garau","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jgar.2020.09.027_bib0010","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","volume":"22","author":"Russo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2020.09.027_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jgar.2018.11.013","article-title":"Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America","volume":"17","author":"Sader","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2020.09.027_bib0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/14656566.2019.1617851","article-title":"Novel developments in the treatment of acute bacterial skin and skin structure infections","volume":"20","author":"Jaffa","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2020.09.027_bib0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1086\/511872","article-title":"Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome","volume":"44","author":"Ruhe","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.027_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.027_bib0035","series-title":"Baxdela (delafloxacin) Prescribing Information. Melinta Therapeutics","author":"Melinta Therapeutics","year":"2019"},{"key":"10.1016\/j.jgar.2020.09.027_bib0040","series-title":"A. Menarini\u2013Industrie Farmaceutiche Riunite\u2013s.r.l. Quofenix, INN\u2013Delafloxacin. Summary of Product Characteristics","year":"2019"},{"key":"10.1016\/j.jgar.2020.09.027_bib0045","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.jgar.2020.09.027_bib0050","series-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 10.0, 2020","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2020"},{"key":"10.1016\/j.jgar.2020.09.027_bib0055","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.09.027_bib0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.027_bib0065","series-title":"27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 22\u201325 April 2017","article-title":"In vitro evaluation of delafloxacin activity when tested against contemporary ABSSSI isolates from Europe and surrounding areas (2014\u20132016): results from the SENTRY Antimicrobial Surveillance Program","author":"Huband","year":"2017"},{"key":"10.1016\/j.jgar.2020.09.027_bib0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.09.027_bib0075","doi-asserted-by":"crossref","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2020.09.027_bib0080","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2020.09.027_bib0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/sur.2015.209","article-title":"Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US medical centers","volume":"17","author":"Sader","year":"2016","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jgar.2020.09.027_bib0090","series-title":"Surveillance of Antimicrobial Resistance in Europe 2018","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2019"},{"key":"10.1016\/j.jgar.2020.09.027_bib0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijid.2019.11.006","article-title":"Antimicrobial activity of cefoperazone\u2013sulbactam tested against Gram-negative organisms from Europe, Asia-Pacific, and Latin America","volume":"91","author":"Sader","year":"2020","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520302551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:41Z","timestamp":1761991121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520302551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":19,"alternative-id":["S2213716520302551"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.09.027","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014\u20132019)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}